Page 14 - Eric Soyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Erytech Pharma S.A.: ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in second-line p...

The event will be held virtually, with all corporate and institutional participants joining remotely. A webcast of the event will be available by clicking here and will be accessible via ERYTECH's website at http://www.erytech.com/investors/webcast/ About ERYTECH and eryaspase ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipelin...

Erytech Pharma S.A.: ERYTECH to Present at the JMP Securities Hematology Summit ERYTECH Pharma cells, t Tuesday December 15 by The event will be held virtually, with all corporate and institutional participants joining remotely. A webcast of the event will be available by clicking hereand will be accessible via ERYTECH's website at http://www.erytech.com/investors/webcast/ About ERYTECH and eryaspase ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAP...